Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Vivos Therapeutics' Accounts Payables rose 9562.79% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 9562.79%. This contributed to the annual value of $1.1 million for FY2024, which is 4881.12% down from last year.
  • Per Vivos Therapeutics' latest filing, its Accounts Payables stood at $2.1 million for Q3 2025, which was up 9562.79% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Vivos Therapeutics' Accounts Payables peaked at $2.5 million during Q1 2024, and registered a low of $644000.0 during Q3 2022.
  • Moreover, its 5-year median value for Accounts Payables was $1.3 million (2021), whereas its average is $1.4 million.
  • In the last 5 years, Vivos Therapeutics' Accounts Payables skyrocketed by 13726.71% in 2023 and then crashed by 5174.07% in 2025.
  • Vivos Therapeutics' Accounts Payables (Quarter) stood at $920000.0 in 2021, then soared by 53.37% to $1.4 million in 2022, then soared by 52.02% to $2.1 million in 2023, then crashed by 48.81% to $1.1 million in 2024, then skyrocketed by 91.53% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $1.8 million for Q2 2025, and $1.2 million during Q1 2025.